2009-12-03 23:05:48 -

Zacks highlights commentary from People and Picks Trader “franklinqq”.

For more Voice of the People, visit at.zacks.com/?id=5851 :

Featured Post


Player “franklinqq” is looking for the next hot drug stock.

“I think it is a dilemma for people whom invested in (NASD: SPPI : ) to make a love-hate comment of it: you can’t imagine how much people loved SPPI when it went up all the way from $0.9 level to $10, but I guess it would be as much as people hate it when its ZEVALIN got FDA approval and SPPI took a nose dive to $4. The “SPPI Big Show” has come to a close, but there is another one ready to start its gorgeous prelude.

If you

take a look of the chart, you will notice that the “DYAX Big Show” already kicked off last week with a sudden jump for $3.20 to $4, and it even broke the 52 weeks high in after hours trading on 11/19. So will it be another 10X myth in the stock market of 2009?


Compared to (NASD: SPPI : ), I would like to say (NASD: DYAX : ) has more qualification for 10X potential.

* DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of hereditary angioedema (HAE).

HAE is an acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities (hands, feet, face, etc.), the gastrointestinal tract, the genitalia, and in potentially life-threatening cases, the larynx.

The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the development and manufacturing of such drugs.

There is no marketed therapy for acute attacks of HAE in the United States, and only one in some European countries. This product is human plasma-derived C1-INH, which replaces the missing or dysfunctional protein. However, it is isolated from human plasma and carries the potential risk of blood-borne pathogens. It is also a non-specific inhibitor of kallikrein, which is thought to be the most relevant target in HAE.

Although the sky-high price and profit margin of Orphan drugs are always target of criticism, as an investor, I concern more on the potential market and profit prospect of DX-88.

*This March, (NASD: DYAX : ) received complete response from FDA in which didn’t required any additional clinical trials for approval of DX-88 but Risk Evaluation and Mitigation Strategy (REMS) and additional information with respect to the chemistry,

manufacturing and controls (CMC) section of the BLA. Dyax believes those were fully addressed in its reply, submitted June 1, 2009.

In June, (NASD: DYAX : ) announced the FDA accepted for review of complete response submission and assigned Dyax’s BLA a new Prescription Drug User Fee Act (PDUFA) action date of December 1, 2009.

This situation is almost the same as SPPI’s. The only difference is that (NASD: DYAX : ) has orphan drug and fast track designation which make it a plus for DX-88’s approval.

*There is always positive reaction in the market for real good drugs and technologies. The indicators include not only the movement of stock price, but also reaction of institutional investors whom have deeper view in the industry. (NASD: DYAX : ) is 55% owned by institutional investors, and we can see the percentage has been increasing since last year. The recent deal was a 5,500,000 common shares for $20,500,000 offering in Oct. The reason I emphasized on institutional investors is that they are not only an evaluation indicator but also a “price engine” for a stock as we already saw on (NASD: SPPI : ) .

*Although DYAX’s stock price already has a big gain since March, it is only at 2007&2008 level. Based on the signals of volumes and price change and market interests, I believe that the big jump on 11/19 would just be the prelude of a big show.

So will (NASD: DYAX : ) be the next 10x myth of 2009? The answer will be uncovered tomorrow.

ATTENTION: For the risk-averse consideration and personal investment strategy, the author himself seldom and don’t advise anybody to bet on FDA approval and earning report data of any stocks. Please do your own research before making any trading decision.”


About the Zacks Community

In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more about People And Picks, visit at.zacks.com/?id=5957 :



About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to at.zacks.com/?id=5958 : .

Follow us on Twitter: twitter.com/ZacksInvestment :

Join us on Facebook: www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553 .. :

Visit www.zacks.com/performance : for information about the performance numbers displayed in this press release.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results.

Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Zacks.comDevin WeissSyndication ManagerPhone:

312-265-9491Email: pr@zacks.com : mailto:pr@zacks.com Visit:
www.Zacks.com :